Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
نویسندگان
چکیده
منابع مشابه
Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
OBJECTIVES To systematically review the effectiveness and cost-effectiveness of palivizumab for the prevention of respiratory syncytial virus (RSV) in children and examine prognostic factors to determine whether subgroups can be identified with important differences in cost-effectiveness. DATA SOURCES Bibliographic databases were searched from inception to March 2007 for literature on the eff...
متن کاملA systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
BACKGROUND Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children, accounting for approximately 75,000-125,000 hospitalizations per year. It is estimated that in 2000, RSV infection accounted for 1.7 million office visits, 402,000 emergency room visits, and 236,000 hospital outpatient visits per year for children younger th...
متن کاملAssociation of RSV-related hospitalization and non-compliance with Palivizumab among commercially insured infants: a retrospective claims analysis
BACKGROUND Palivizumab has been shown to decrease the incidence of hospitalization due to respiratory syncytial virus (RSV) in infants at risk of severe RSV disease. We examined the association between compliance with palivizumab dosing throughout the RSV season and risk of RSV-related hospitalization in clinical practice. METHODS Subjects who were born and discharged from the hospital before...
متن کاملAAP Issues Updated Guidance on Palivizumab Prophylaxis for RSV Infection.
Volume 90, Number 12 www.aafp.org/afp American Family Physician 867 The American Academy of Pediatrics (AAP) Committee on Infectious Diseases has updated its guidance on the use of palivizumab (Synagis) prophylaxis in infants and children at increased risk of respiratory syncytial virus (RSV) infection. Because the palivizumab package labeling does not include a definition of high-risk children...
متن کاملRevised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity. The lack of effective treatments for bronchiolitis and the lack of vaccines for RSV accentuate the role of prevention in decreasing the impact of this disease. Pr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ Paediatrics Open
سال: 2021
ISSN: 2399-9772
DOI: 10.1136/bmjpo-2020-000985